Neuren pays the price for sellside froth
The Australian group has found a partner for its lead asset at last, so why is the stock down?
FDA’s flashing green light boosts novel drug approvals
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.
